Press Releases
Jennerex Announces Expansion of Intellectual Property Portfolio
-Strengthening of Pexa-Vec and platform patent coverage in the US, China and Australia -
San Francisco, Calif. -- September 28, 2013 — Jennerex Biotherapeutics today announced key additions to its patent portfolio for its proprietary SOLVE™ platform. The expanded intellectual property include licenses and new patent issuances covering vaccinia engineering, administration and dosing. The licenses and patents include composition and use of vaccinia in the United States, China and Australia.
"This broadening of our IP portfolio strengthens the value of our pipeline of vaccinia-based oncolytic immunotherapies" said Laurent Fischer, MD, chairman and CEO of Jennerex. "As we advance the Pexa-Vec phase 2 program, we continue to increase the depth of the SOLVE™ platform and build prospects for additional innovative therapies beyond Pexa-Vec."
Jennerex is advancing Phase 2 studies with Pexa-Vec in colorectal cancer, kidney cancer and ovarian cancer and evaluating data from the multiple Phase 2 primary liver cancer studies recently completed. The Jennerex pipeline also includes JX-929, an oncolytic immunotherapy in Phase 1 clinical trials, and a platform for novel oncolytic and antibody-based immunotherapies. Jennerex anticipates data from both Pexa-Vec and JX-929 in multiple tumor types over the next 12 months.
About Jennerex
Jennerex Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of groundbreaking oncolytic immunotherapies for patients with life-threatening cancers. The company's lead product candidate, Pexa-Vec (JX-594), is in mid-stage clinical development for the treatment of advanced primary liver cancer, colorectal cancer, kidney cancer and ovarian cancer, and its next generation product candidate, JX-929, is under investigation for a variety of other solid tumors. Jennerex is headquartered in San Francisco and has related research and development operations in Ottawa, Canada and South Korea. Pexa-Vec is partnered in Europe with Transgene, a member of the Institute Merieux group, in South Korea with Green Cross Corporation and in China with Lee's Pharmaceutical Holdings. For more information about Jennerex, please visit www.jennerex.com.
Back to Top
